Proteonomix PROT.PK von 1$ auf 3 $ innerhalb von 2 Wochen, kommt da noch mehr??? - 500 Beiträge pro Seite
eröffnet am 04.03.10 15:34:15 von
neuester Beitrag 02.06.10 16:29:03 von
neuester Beitrag 02.06.10 16:29:03 von
Beiträge: 4
ID: 1.156.363
ID: 1.156.363
Aufrufe heute: 0
Gesamt: 362
Gesamt: 362
Aktive User: 0
ISIN: US74371C2089 · WKN: A0Q8B7 · Symbol: PROT
0,0000
USD
0,00 %
0,0000 USD
Letzter Kurs 21.12.23 Nasdaq OTC
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,3500 | +29,82 | |
| 1,5700 | +25,60 | |
| 0,6000 | +25,26 | |
| 4,5700 | +24,18 | |
| 1,8300 | +23,65 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,7603 | -15,56 | |
| 0,7008 | -15,56 | |
| 2,8600 | -19,21 | |
| 27,00 | -49,30 | |
| 3,4100 | -53,67 |
Feedback
Waren ja schon mal bei 11$...www.proteonomix.com
Gerüchte aus USA besagen, dass sie bald ans Bulletin Board Wechseln und eine Übernahme kurz bevorsteht...
Mit einer Marketcap von derzeit 14 Mio $ können sie sich als Stammzellenplay meiner Meinung nach locker nochmal verdoppeln...
Die letzten Meldungen können sich wirklich sehen lassen:
MOUNTAINSIDE, NJ--(Marketwire - 02/25/10) - Proteonomix, Inc. (Pinksheets:PROT - News) announces the appointment of Ashoke Agarwal, M.D., F.A.C.C. as Chief Scientific Officer of its subsidiary, StromaCel, Inc.
Dr. Agarwal, 62 years old, is also Chief Scientific Officer for the Company's subsidiary, National Stem Cell, Inc. He has been in private practice in the fields of Internal Medicine and Cardiology since 1983 and is affiliated with four hospitals in New Jersey. He was formerly Chairman of the Department of Medicine (1996-1998) and Section Chief of the Department of Cardiology (1999 - 2002) at Barnert Hospital, Paterson, New Jersey. He also served as Section Chief, Division of Cardiology at Passaic Beth Israel Hospital (1994 - 1996). He is a member of a number of medical societies and committees including the New Jersey State Medical Society (since 1984). Dr. Agarwal is past president of the Passaic County Medical Society. He received his medical degree at the Medical College, Calcutta, India, in 1969.
Dr. Agarwal is a member of the American College of Cardiology and a Fellow of the American College of Cardiology (F.A.C.C.), a leading professional society representing heart specialists in the United States and abroad. Members of the F.A.C.C. include adult cardiologists, pediatric cardiologists, cardiovascular surgeons, researchers and academicians, and specialists in a cardiovascular-related field. Dr. Agarwal is certified in Internal Medicine by the American Board of Internal Medicine.
Michael Cohen, President of Proteonomix, stated: "Dr. Agarwal has served as Chief Scientific Officer of our subsidiary, National Stem Cell, Inc. and has contributed to our research into stem cell therapies for cardiac disease. We welcome his talents and knowledge to guide the development of therapies in StromaCel, Inc., our new subsidiary."
Dr. Agarwal stated: "I look forward to integrating my professional expertise and background with the development of regenerative medicine planned to be developed by StromaCel."
StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Please visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.pinksheets.com/ and http://www.sec.gov/ for further information about Proteonomix.
Certain statements contained herein are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that the statements made in this press constitute forward-looking statements and makes no guarantees of future performance and actual results or developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at time the statements are made.
Gerüchte aus USA besagen, dass sie bald ans Bulletin Board Wechseln und eine Übernahme kurz bevorsteht...
Mit einer Marketcap von derzeit 14 Mio $ können sie sich als Stammzellenplay meiner Meinung nach locker nochmal verdoppeln...
Die letzten Meldungen können sich wirklich sehen lassen:
MOUNTAINSIDE, NJ--(Marketwire - 02/25/10) - Proteonomix, Inc. (Pinksheets:PROT - News) announces the appointment of Ashoke Agarwal, M.D., F.A.C.C. as Chief Scientific Officer of its subsidiary, StromaCel, Inc.
Dr. Agarwal, 62 years old, is also Chief Scientific Officer for the Company's subsidiary, National Stem Cell, Inc. He has been in private practice in the fields of Internal Medicine and Cardiology since 1983 and is affiliated with four hospitals in New Jersey. He was formerly Chairman of the Department of Medicine (1996-1998) and Section Chief of the Department of Cardiology (1999 - 2002) at Barnert Hospital, Paterson, New Jersey. He also served as Section Chief, Division of Cardiology at Passaic Beth Israel Hospital (1994 - 1996). He is a member of a number of medical societies and committees including the New Jersey State Medical Society (since 1984). Dr. Agarwal is past president of the Passaic County Medical Society. He received his medical degree at the Medical College, Calcutta, India, in 1969.
Dr. Agarwal is a member of the American College of Cardiology and a Fellow of the American College of Cardiology (F.A.C.C.), a leading professional society representing heart specialists in the United States and abroad. Members of the F.A.C.C. include adult cardiologists, pediatric cardiologists, cardiovascular surgeons, researchers and academicians, and specialists in a cardiovascular-related field. Dr. Agarwal is certified in Internal Medicine by the American Board of Internal Medicine.
Michael Cohen, President of Proteonomix, stated: "Dr. Agarwal has served as Chief Scientific Officer of our subsidiary, National Stem Cell, Inc. and has contributed to our research into stem cell therapies for cardiac disease. We welcome his talents and knowledge to guide the development of therapies in StromaCel, Inc., our new subsidiary."
Dr. Agarwal stated: "I look forward to integrating my professional expertise and background with the development of regenerative medicine planned to be developed by StromaCel."
StromaCel's goal is to study the basic cellular properties of stromal cells and to identify the utility of cellular and protein derivatives in disease repair.
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Please visit http://www.proteonomix.com/, http://www.proteoderm.com/, http://www.pinksheets.com/ and http://www.sec.gov/ for further information about Proteonomix.
Certain statements contained herein are "forward-looking" statements (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that the statements made in this press constitute forward-looking statements and makes no guarantees of future performance and actual results or developments may differ materially from projections in forward-looking statements. Forward-looking statements are based on estimates and opinions of management at time the statements are made.
Antwort auf Beitrag Nr.: 39.059.622 von Raider1 am 04.03.10 15:34:15Nun bald am OTC Bulletinboard...
Proteonomix, Inc. (PROT) Announces That It Has Cleared Comments in Its Registration Statement Filed With the Securities and Exchange Commission and Is Applying for a Listing on the OTCBB
Buzz up! 0 Print..Companies:Proteonomix, Inc..Related Quotes
Symbol Price Change
PROT.PK 3.00 +0.05
{"s" : "prot.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Proteonomix On Thursday April 22, 2010, 12:15 pm
MOUNTAINSIDE, NJ--(Marketwire - 04/22/10) - Proteonomix, Inc. (Pinksheets:PROT - News) announces it has received a no comment letter from the Securities and Exchange Commission on its registration statement on Form 10 pursuant of the Securities Exchange Act of 1934. The no comment letter permits the company to file with FINRA through a broker-dealer for a listing of its common stock on the OTC Bulletin Board. Proteonomix is supplying documentation to a registered broker-dealer for a listing on its behalf.
The Company has traded on the Pink Sheets and more recently on the OTCQB. Since October 5, 2009, it has filed reports with the SEC, including quarterly reports on Form 10-Q, an annual report on Form 10-K and reports on Form 8-K. In addition, its affiliates have reported their acquisition and sale of Proteonomix securities on Form 3 and Form 4.
Michael Cohen, President, stated: "We have always tried to be transparent in the disclosure of our business and finances and intend to be current in reports filed with the SEC. Our receipt of this SEC no-comment letter on our registration statement allows us the opportunity to list on the OTCBB market. An OTCBB listing will add to the credibility of the disclosure of our technological and therapeutic advances, and also exposes our company to clients of firms that do not presently allow their representatives to recommend our common stock. Finally, a listing on the OTCBB will provide a greater opportunity for institutions to become involved in PROT."
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm has developed a line of anti-aging cosmetics. Please visit http://www.proteonomix.com/, www.proteoderm.com, http://www.otcqb.com/ and www.sec.gov.
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release relating to its OTCBB listing constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made
Proteonomix, Inc. (PROT) Announces That It Has Cleared Comments in Its Registration Statement Filed With the Securities and Exchange Commission and Is Applying for a Listing on the OTCBB
Buzz up! 0 Print..Companies:Proteonomix, Inc..Related Quotes
Symbol Price Change
PROT.PK 3.00 +0.05
{"s" : "prot.pk","k" : "a00,a50,b00,b60,c10,g00,h00,l10,p20,t10,v00","o" : "","j" : ""} Press Release Source: Proteonomix On Thursday April 22, 2010, 12:15 pm
MOUNTAINSIDE, NJ--(Marketwire - 04/22/10) - Proteonomix, Inc. (Pinksheets:PROT - News) announces it has received a no comment letter from the Securities and Exchange Commission on its registration statement on Form 10 pursuant of the Securities Exchange Act of 1934. The no comment letter permits the company to file with FINRA through a broker-dealer for a listing of its common stock on the OTC Bulletin Board. Proteonomix is supplying documentation to a registered broker-dealer for a listing on its behalf.
The Company has traded on the Pink Sheets and more recently on the OTCQB. Since October 5, 2009, it has filed reports with the SEC, including quarterly reports on Form 10-Q, an annual report on Form 10-K and reports on Form 8-K. In addition, its affiliates have reported their acquisition and sale of Proteonomix securities on Form 3 and Form 4.
Michael Cohen, President, stated: "We have always tried to be transparent in the disclosure of our business and finances and intend to be current in reports filed with the SEC. Our receipt of this SEC no-comment letter on our registration statement allows us the opportunity to list on the OTCBB market. An OTCBB listing will add to the credibility of the disclosure of our technological and therapeutic advances, and also exposes our company to clients of firms that do not presently allow their representatives to recommend our common stock. Finally, a listing on the OTCBB will provide a greater opportunity for institutions to become involved in PROT."
Proteonomix is a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives. Proteonomix has facilities at a number of academic institutions. Its subsidiary, Proteoderm has developed a line of anti-aging cosmetics. Please visit http://www.proteonomix.com/, www.proteoderm.com, http://www.otcqb.com/ and www.sec.gov.
Certain statements contained herein are "forward-looking statements" (as defined in the Private Securities Litigation Reform Act of 1995). Proteonomix, Inc. cautions that statements made in this press release relating to its OTCBB listing constitute forward-looking statements and makes no guarantee of future performance. Actual results or developments may differ materially from projections. Forward-looking statements are based on estimates and opinions of management at the time statements are made
Die Zeit zum aussteigen ist meiner Meinung nach in kürze da
Antwort auf Beitrag Nr.: 39.593.444 von gerdass am 27.05.10 15:24:04Sieht doch super aus, bis jetzt.
Wenn man sich mal den Chart betrachtet, kann es mit entsprechenden News auch auf 7,50 oder 10 Dollar gehen, da waren sie ja schon mal...
Auch im Vergleich mit anderen Stammzellenplays sind sie noch nicht gerade überbewertet...
Wenn man sich mal den Chart betrachtet, kann es mit entsprechenden News auch auf 7,50 oder 10 Dollar gehen, da waren sie ja schon mal...
Auch im Vergleich mit anderen Stammzellenplays sind sie noch nicht gerade überbewertet...
DurchsuchenBeitrag zu dieser Diskussion schreiben
Zu dieser Diskussion können keine Beiträge mehr verfasst werden, da der letzte Beitrag vor mehr als zwei Jahren verfasst wurde und die Diskussion daraufhin archiviert wurde.
Bitte wenden Sie sich an feedback@wallstreet-online.de und erfragen Sie die Reaktivierung der Diskussion oder starten Sie eine neue Diskussion.
Meistdiskutiert
| Wertpapier | Beiträge | |
|---|---|---|
| 218 | ||
| 155 | ||
| 76 | ||
| 58 | ||
| 49 | ||
| 45 | ||
| 44 | ||
| 41 | ||
| 36 | ||
| 29 |
| Wertpapier | Beiträge | |
|---|---|---|
| 25 | ||
| 25 | ||
| 23 | ||
| 21 | ||
| 21 | ||
| 21 | ||
| 20 | ||
| 19 | ||
| 19 | ||
| 19 |
